EVP Finance/CFO of Salix Pharmaceuticals Ltd. (SLXP, Financial) Adam C Derbyshire sells 5,000 shares of SLXP on 11/25/2009 at an average price of $23.58 a share.
Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialtypharmaceutical company focussed on the needs of physicians specializing ingastroenterology. The company intends to establish a small direct sales force to promote its products to this specialist audience. The company's strategy is to identify and acquire products that have near-term commercial potential and apply its regulatory and product development expertise to commercialize these products. The company selects products that it believes serve a gastrointestinal disease. Salix Pharmaceuticals Ltd. has a market cap of $1.11 billion; its shares were traded at around $22.79 with and P/S ratio of 6.22.
Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialtypharmaceutical company focussed on the needs of physicians specializing ingastroenterology. The company intends to establish a small direct sales force to promote its products to this specialist audience. The company's strategy is to identify and acquire products that have near-term commercial potential and apply its regulatory and product development expertise to commercialize these products. The company selects products that it believes serve a gastrointestinal disease. Salix Pharmaceuticals Ltd. has a market cap of $1.11 billion; its shares were traded at around $22.79 with and P/S ratio of 6.22.
Insiders' Positions with SLXP
- Sell:: President & CEO Carolyn J Logan sold 10,000 shares of SLXP stock on 09/14/2009 at the average price of 20.67, the price of the stock has increased by 10.26% since
- Sell:: President & CEO Carolyn J Logan sold 10,000 shares of SLXP stock on 09/14/2009 at the average price of 20.67, the price of the stock has increased by 10.26% since
Insiders' Positions with SLXP
- Sell:: EVP Finance/CFO Adam C Derbyshire sold 5,000 shares of SLXP stock on 11/18/2009 at the average price of 21.05, the price of the stock has increased by 8.27% since
- Sell:: EVP Finance/CFO Adam C Derbyshire sold 5,000 shares of SLXP stock on 11/11/2009 at the average price of 20.12, the price of the stock has increased by 13.27% since
- Sell:: EVP Finance/CFO Adam C Derbyshire sold 5,000 shares of SLXP stock on 11/04/2009 at the average price of 19.7, the price of the stock has increased by 15.69% since
- Sell:: EVP Finance/CFO Adam C Derbyshire sold 5,000 shares of SLXP stock on 10/28/2009 at the average price of 19.79, the price of the stock has increased by 15.16% since
- Sell:: EVP Finance/CFO Adam C Derbyshire sold 5,000 shares of SLXP stock on 10/21/2009 at the average price of 21, the price of the stock has increased by 8.52% since
Insiders' Positions with SLXP
- Buy:: Director Mark A Sirgo bought 950 shares of SLXP stock on 08/14/2009 at the average price of 12.46, the price of the stock has increased by 82.91% since
- Sell:: Gen Counsel&VP Corp Compliance Mark D Reeth sold 3,377 shares of SLXP stock on 11/23/2009 at the average price of 23.64, the price of the stock has decreased by 3.6% since
- Sell:: James E Flynn sold 1,025,953 shares of SLXP stock on 09/10/2009 at the average price of 13.09, the price of the stock has increased by 74.1% since
- Sell:: James E Flynn sold 80,921 shares of SLXP stock on 08/19/2009 at the average price of 12.96, the price of the stock has increased by 75.85% since
- Sell:: Director Richard A Franco sold 5,200 shares of SLXP stock on 08/14/2009 at the average price of 12.57, the price of the stock has increased by 81.3% since
